Published in Cold Spring Harb Perspect Med on October 01, 2013
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin Microbiol Rev (2014) 0.79
Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections. Oxid Med Cell Longev (2014) 0.77
Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation. JCI Insight (2016) 0.77
Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease. Respir Res (2016) 0.75
Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review. Rev Paul Pediatr (2016) 0.75
Clinical and microbiological profile of chronic Burkholderia cepacia complex infections in a cystic fibrosis reference hospital in Brazil. Eur J Clin Microbiol Infect Dis (2017) 0.75
Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med (1995) 6.56
Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med (1995) 4.82
Cystic fibrosis. Am J Respir Crit Care Med (1996) 4.56
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med (2007) 4.34
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol (2003) 4.13
Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med (2008) 3.91
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet (1985) 3.32
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med (2008) 2.63
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med (2010) 2.40
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med (1994) 2.26
The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol (1995) 2.12
Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ (1995) 2.12
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax (2009) 2.10
Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med (1999) 2.08
IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol (2006) 2.06
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med (1997) 2.00
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J (2006) 1.98
Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985) (1993) 1.88
State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res (2003) 1.86
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr (2007) 1.86
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol (1995) 1.82
Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros (2012) 1.79
Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med (2000) 1.78
Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis (1997) 1.76
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr (1995) 1.75
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med (2007) 1.75
Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest (1998) 1.71
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA (2010) 1.69
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol (1997) 1.68
Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem (2003) 1.67
A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest (2005) 1.65
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2002) 1.54
Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis. Eur Respir J (2010) 1.52
Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child (1996) 1.50
Glutathione permeability of CFTR. Am J Physiol (1998) 1.48
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A (2006) 1.47
Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol (1997) 1.43
A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol (2003) 1.39
Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol (1999) 1.38
A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A (1999) 1.37
Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol (1998) 1.34
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol (2011) 1.25
Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med (2005) 1.21
Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol (1985) (2002) 1.20
Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis (1993) 1.20
Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax (1997) 1.18
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol (2004) 1.17
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol (2010) 1.14
IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med (1999) 1.13
Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol (2001) 1.10
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest (2011) 1.09
Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med (2011) 1.09
Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS One (2008) 1.08
Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med (2002) 1.08
Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med (1996) 1.07
Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res (2002) 1.05
Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis (1993) 1.05
Is cystic fibrosis a TH17 disease? Inflamm Res (2007) 1.05
Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther (2003) 1.04
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax (2012) 1.04
Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol (2008) 1.03
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med (2006) 1.02
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros (2012) 0.98
The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol (2009) 0.97
Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr Res (2009) 0.96
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res (2010) 0.94
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med (2008) 0.94
Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol (2001) 0.93
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol (2005) 0.93
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res (1997) 0.92
Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
Exacerbations in cystic fibrosis: 3--Management. Thorax (2008) 0.92
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax (2012) 0.91
Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids (2008) 0.89
Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med (2005) 0.89
Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J (2005) 0.87
Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2002) 0.85
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros (2012) 0.85
Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Thorax (2012) 0.85
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev (2007) 0.84
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2012) 0.84
Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J Pathol (2006) 0.83
The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs (2009) 0.80
The new microbiology of cystic fibrosis: it takes a community. Thorax (2012) 0.79
Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med (2003) 0.78
Use of cyclosporin A as a steroid sparing agent in cystic fibrosis. Arch Dis Child (2001) 0.77
Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. Respir Med (2003) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med (2008) 3.91
Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med (2014) 3.50
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med (2009) 2.52
Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury. Crit Care Med (2010) 2.49
Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med (2013) 2.08
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One (2012) 2.03
Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med (2002) 1.88
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros (2012) 1.79
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA (2010) 1.69
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol (2002) 1.67
A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med (2010) 1.67
Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol (2007) 1.67
Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2004) 1.65
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol (2007) 1.46
MRSA in companion animals. Vet Rec (2006) 1.40
Respiratory viral infection in exacerbations of COPD. Respir Med (2008) 1.35
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr (2009) 1.31
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med (2007) 1.29
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother (2011) 1.26
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res (2011) 1.21
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol (2007) 1.19
Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). J Cyst Fibros (2010) 1.17
Dysregulated apoptosis and NFkappaB expression in COPD subjects. Respir Res (2009) 1.12
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest (2011) 1.09
Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med (2002) 1.08
Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol (2009) 1.07
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros (2014) 1.06
Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther (2007) 1.04
Early detection of Pseudomonas aeruginosa--comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann Clin Microbiol Antimicrob (2004) 1.04
Clinical trials in cystic fibrosis. J Cyst Fibros (2007) 1.03
A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med (2009) 1.03
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med (2006) 1.02
Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis). J Clin Microbiol (2003) 1.01
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros (2013) 1.00
Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros (2010) 1.00
Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc (2014) 1.00
Staphylococcus aureus enterotoxins induce IL-8 secretion by human nasal epithelial cells. Respir Res (2006) 1.00
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol (2006) 0.99
Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol (2010) 0.99
Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr (2011) 0.99
Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol (2010) 0.99
Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med (2006) 0.98
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros (2012) 0.98
The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol (2007) 0.97
Impact of pregnancy on women with cystic fibrosis. Chest (2006) 0.97
Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol (2008) 0.97
An international randomized multicenter comparison of nasal potential difference techniques. Chest (2010) 0.96
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One (2011) 0.95
Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics (2007) 0.95
Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol (2011) 0.95
The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol (2007) 0.95
Molecular detection of CF lung pathogens: current status and future potential. J Cyst Fibros (2013) 0.95
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res (2010) 0.94
Biomarkers of fruit and vegetable intake in human intervention studies: a systematic review. Crit Rev Food Sci Nutr (2011) 0.94
Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem Soc Trans (2009) 0.94
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol (2002) 0.94
Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res (2012) 0.93
Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol (2004) 0.93
Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis. J Antimicrob Chemother (2010) 0.93
Validity and reliability of cardiorespiratory measurements recorded by the LifeShirt during exercise tests. Respir Physiol Neurobiol (2009) 0.92
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2012) 0.92
Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros (2012) 0.92
Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med (2005) 0.92
Development of a diagnostic PCR assay that targets a heat-shock protein gene (groES) for detection of Pseudomonas spp. in cystic fibrosis patients. J Med Microbiol (2003) 0.92
Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol (2013) 0.91
Acute and latent adenovirus in COPD. Respir Med (2007) 0.91
Bronchial epithelial cell growth regulation in fibroblast cocultures: the role of hepatocyte growth factor. Am J Physiol Lung Cell Mol Physiol (2007) 0.90
Pandoraea apista isolated from a patient with cystic fibrosis: problems associated with laboratory identification. Br J Biomed Sci (2002) 0.90
Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self-report and bio-chemical validation. Int J Nurs Stud (2011) 0.90
Inflammatory mediators in CF patients. Methods Mol Med (2002) 0.90
Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers. Eur Respir J (2012) 0.89
Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr (2006) 0.89
Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol (2008) 0.89
Comparison of nasal and bronchial epithelial cells obtained from patients with COPD. PLoS One (2012) 0.88
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. Pediatr Pulmonol (2012) 0.88
Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother (2013) 0.88
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros (2011) 0.88
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 0.87
Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J Antimicrob Chemother (2009) 0.87
Effect of Aspergillus fumigatus and Candida albicans on pro-inflammatory response in cystic fibrosis epithelium. J Cyst Fibros (2011) 0.87
Effect of cystic fibrosis exacerbations on neutrophil function. Int Immunopharmacol (2005) 0.87